Current Atherosclerosis Reports

Papers
(The H4-Index of Current Atherosclerosis Reports is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know124
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?82
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions75
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?72
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis67
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management64
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment57
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?54
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management51
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?51
The Effects of FABP4 on Cardiovascular Disease in the Aging Population51
Ambient Air Pollution and Atherosclerosis: Recent Updates48
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice46
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–202046
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future45
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond44
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators44
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm39
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women37
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease36
The Genetic Basis of Hypertriglyceridemia36
The Emerging Specialty of Cardio-Rheumatology34
RNA Silencing in the Management of Dyslipidemias34
Percutaneous Coronary Interventions in Women33
Inflammation in the Peri-ACS Period: Ready for Prime Time?33
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women30
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention30
mHealth Technology and CVD Risk Reduction30
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?30
0.2712869644165